NanoViricides to Present Broad-Spectrum Antiviral Platform at LSX World Congress 2025

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs designed to resist viral escape, will present at the Life Science Executive Partnering (LSX) World Congress 2025 in Boston on September 17. The company's presentation will focus on its novel nanoviricide technology platform, which represents a significant advancement in antiviral therapeutics by addressing the critical challenge of viral mutation and drug resistance.

The company's lead drug candidate, NV-387, is being developed as a broad-spectrum antiviral treatment for respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox infections. Another advanced candidate, NV-HHV-1, targets the treatment of shingles. The platform's importance lies in its ability to potentially treat multiple viral diseases with a single technological approach, addressing the growing concern of antiviral resistance and pandemic preparedness.

NanoViricides has developed two specific COVID-19 drug candidates: NV-CoV-2, which does not encapsulate remdesivir, and NV-CoV-2-R, which incorporates remdesivir within its polymeric micelles. The company believes that since remdesivir is already FDA-approved, its drug candidate encapsulating remdesivir is likely to be approvable if safety profiles are comparable. Additional development programs target oral and genital herpes, viral eye diseases including EKC and herpes keratitis, various influenza strains, HIV, hepatitis C, rabies, dengue fever, and Ebola virus.

The company's technology is based on intellectual property licensed from TheraCour Pharma Inc., with exclusive, sub-licensable field licenses for specific viral applications. According to the company's latest updates available at https://ibn.fm/NNVC, NanoViricides holds perpetual worldwide exclusive licenses for several drugs targeting HIV/AIDS, hepatitis viruses, rabies, herpes viruses, influenza strains, dengue viruses, and coronaviruses among others. The platform's broad applicability across multiple viral families underscores its potential significance in global health security.

However, the company acknowledges the inherent risks of drug development, noting that the path to pharmaceutical product approval is extremely lengthy and requires substantial capital. There can be no assurance that any of its candidates will show sufficient effectiveness and safety for human clinical development, nor that successful laboratory results will translate to successful clinical trials or commercial products. The presentation at LSX World Congress represents an important opportunity for the company to showcase its technology to potential partners and investors in the life sciences community.